Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brainshuttle AD multiple-ascending dose study of RO7126209 (trontinemab) in prodromal or mild to moderate Alzheimer’s disease
2023-509678-52-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab IV with Placebo IV (2 arms). Primary endpoints: Safety and tolerability of trontinemab (RO7126209) and Change from baseline in brain amyloid load (Part 3 primary). Planned start Mar 2024; status: authorised.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-509678-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509678-52-00.